TY - JOUR
TI - 3,6-disubstituted 1,2,4-triazolo[3,4-b] thiadiazoles with anticancer activity targeting topoisomerase II alpha
AU - Sagredou, S.
AU - Dalezis, P.
AU - Nikoleousakos, N.
AU - Nikolaou, M.
AU - Voura, M.
AU - Almpanakis, K.
AU - Panayiotidis, M.I.
AU - Sarli, V.
AU - Trafalis, D.T.
JO - OncoTargets and therapy
PY - 2020
VL - 13
TODO - null
SP - 7369-7386
PB - Dove Medical Press Ltd
SN - null
TODO - 10.2147/OTT.S254856
TODO - 1,2,4 triazolo[3,4 b]thiadiazole derivative;  2 (2 hydrazinyl 2 oxoethyl) n,n dimethyl 4,5 dimethoxybenzenesulfonamide;  2 [(4 amino 5 mercapto 4h 1,2,4 triazol 3 Yl) methyl] n,n dimethyl 4,5 dimethoxybenzene sulfonamide;  2 [[6 (2,5 dinitrophenyl) [1,2,4]triazolo[3,4 b][1,3,4]thiadiazol 3 yl]methyl] 4,5 dimethoxy n,n dimethylbenzenesulfonamide;  2 [[6 (4 chlorostyryl) [1,2,4]triazolo[3,4 b][1,3,4]thiadiazol 3 yl]methyl] 4,5 dimethoxy n,n dimethylbenzenesulfonamide;  2 [[6 (4 fluorostyryl) [1,2,4]triazolo[3,4 b][1,3,4]thiadiazol 3 yl]methyl] 4,5 dimethoxy n,n dimethylbenzenesulfonamide;  antineoplastic agent;  DNA topoisomerase (ATP hydrolysing);  methyl 2 (3,4 dimethoxyphenyl)acetate;  methyl 2 [2 (chlorosulfonyl) 4,5 dimethoxyphenyl]acetate;  methyl 2 [2 (n,n dimethylsulfamoyl) 4,5 dimethoxyphenyl]acetate;  topoisomerase 2 alpha;  unclassified drug, antineoplastic activity;  antiproliferative activity;  apoptosis;  Article;  cell cycle arrest;  cell free system;  DLD-1 cell line;  drug screening;  drug structure;  drug synthesis;  enzyme phosphorylation;  GI50;  HT-29 cell line;  human;  human cell;  IC50;  in vitro study;  LoVo cell line;  MTT assay;  protein targeting
TODO - Background: Topoisomerase IIα (topIIα) maintains the topology of DNA in order to ensure the proper functioning of numerous DNA processes. Inhibition of topIIα leads to the killing of cancer cells thus constituting such inhibitors as useful tools in cancer therapeutics. Triazolo[3,4-b]thiadiazole derivatives are known for their wide range of pharmacological activities while previous studies have documented their in vitro anticancer activity. The purpose of the current study was to investigate if these chemical compounds can act as topIIα inhibitors in cell-free and cell-based systems. Materials and Methods: The MTT assay was performed in DLD-1, HT-29, and LoVo cancer cells so as to evaluate the antiproliferative activity of KA25, KA26, and KA39 triazolo[3,4-b]thiadiazole derivatives. The KA39 compound was tested as a potential topIIα inhibitor using the plasmid-based topoisomerase II drug screening kit. The inhibitory effect of the three derivatives on topIIα phosphorylation was studied in HT-29 and LoVo cancer cells according to Human Phospho-TOP2A/Topoisomerase II Alpha Cell-Based Phosphorylation ELISA Kit. Moreover, flow cytometry was utilized in order to explore apoptotic induction and cell cycle growth arrest, upon treatment with KA39, in DLD-1 and HT-29 cells, respectively. In silico studies were also carried out for further investigation. Results: All three triazolo[3,4-b]thiadiazole derivatives showed an in vitro antiproliferative effect with the KA39 compound being the most potent one. Our results indicated that KA39 induced both early and late apoptosis as well as cell cycle growth arrest in S phase. In addition, the compound blocked the relaxation of supercoiled DNA while it also inhibited topIIα phosphorylation (upon treatment; P<0.001). Conclusion: Among the three triazolo[3,4-b]thiadiazole derivatives, KA39 was shown to be the most potent anticancer agent and catalytic inhibitor of topIIα phosphorylation as well. © 2020 Sagredou et al.
ER -